



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/204790/>

Version: Supplemental Material

Article:

Mohajer, B., Moradi, K., Guermazi, A. et al. (2024) Statin use and longitudinal changes in quantitative MRI-based biomarkers of thigh muscle quality: data from Osteoarthritis Initiative. *Skeletal Radiology*, 53. pp. 683-695. ISSN: 0364-2348

<https://doi.org/10.1007/s00256-023-04473-7>

© The Author(s), under exclusive licence to International Skeletal Society (ISS) 2023. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use (<https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms>), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: <https://doi.org/10.1007/s00256-023-04473-7>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

TABLE OF CONTENTS

Supplemental Methods	2
Reasoning for utilizing biomarkers of muscle quality	2
Variables incorporated in propensity-score matching.....	2
Assessment of missing data pattern using Little's test	3
Supplemental Tables	4
Supplemental Table 1. Osteoarthritis Initiative (OAI) datasets used in the analysis.....	4
Supplemental Table 2. Percentage of missing data of the covariate included in the multiple imputations and PS-matching methods.....	6
Supplemental Table 3. Baseline characteristics of study groups as with and without/at-risk of KOA, included in the study before and after propensity-score matching according to statin use.	8
Supplemental Table 4. Baseline characteristics of the study participants included in sensitivity analysis of exclusion of participants with adherent and prevalent statin use (Sensitivity analysis #1) before and after propensity score matching according to statin use.	19
Supplemental Table 5. Sensitivity analysis results.	26
Supplemental Figures	29
Supplemental Figure 1. Illustration of the study muscle biomarkers.....	29
Appendix References	30

Supplemental Methods

Reasoning for utilizing biomarkers of muscle quality

Traditional methods of evaluating statin-related muscle adverse effects have relied on changes in muscle strength and contractile force (7,8). However, these measures can be affected by muscle atrophy, which may be caused by muscle disuse associated with potential statin-associated muscle symptoms (SAMS) or other comorbidities in statin users, such as insufficient physical activity (9). Consequently, while muscle strength is commonly used to assess muscle atrophy and is easily measured, it may not be sensitive enough to detect early changes in muscle quality resulting from statin use. Recent studies have demonstrated that magnetic resonance imaging (MRI) of the muscle is a reliable, sensitive, and precise noninvasive tool for monitoring the development and progression of myopathies. Furthermore, MRI can accurately quantify muscle quality, regardless of muscle atrophy (i.e., loss of muscle volume) (10-18). These MRI measures have been extensively employed in various neuromuscular disorders, diabetes mellitus, obesity, stroke, and other conditions that affect muscle mass and composition (11-15).

Variables incorporated in propensity-score matching

The variables included in propensity-score matching (PS-matching) encompassed age (in years), gender (male/female), race/ethnicity (White or non-white race), body-mass index (BMI, Weight/(Height)² in Kg/m²), physical activity scale for the elderly score (PASE), abdominal obesity (defined as a waist circumference of ≥ 94 cm in men and ≥ 80 cm in women, according to the international diabetes foundation criteria) (19), alcohol consumption (number of drinks consumed per week during the last 12 months, categorized as none, <1/week, 1-3 drinks/week, 4-7 drinks/week, 8-14 drinks/week, 15 drinks or more), smoking (smoking pipe, cigars, or cigarillos

categorized as never, past smoker, currently smoking <14 cigarettes/day, currently smoking >14 cigarettes/day), diabetes (self-reported diabetes or use of oral or injective diabetes medications, yes/no), hypertension (Physical examination at OAI baseline visit, indexed as systolic blood pressure of ≥ 130 mm/Hg or diastolic blood pressure of ≥ 80 mm Hg, yes/no), cerebrovascular accident (self-reported history of stroke, cerebrovascular accident, blood clot or bleeding in brain, or transient ischemic attack), heart attack (self-reported history of heart attack, yes/no), heart failure (self-reported history of having heart failure or receiving treatment for heart failure, yes/no), peripheral artery disease (self-reported, yes/no), malignancy (self-reported history of cancer, other than skin cancer, leukemia or lymphoma, yes/no), chronic obstructive pulmonary disease (self-reported, having emphysema, chronic bronchitis, or chronic obstructive lung disease, yes/no), kidney dysfunction (self-reported, ever had a problem with kidneys, poor kidney function based on high blood creatinine, yes/no), advanced liver dysfunction (self-reported, have cirrhosis or serious liver damage, yes/no), peptic ulcer (self-reported stomach ulcers or peptic ulcer disease, yes/no), Charlson comorbidity score (calculated from the list of comorbidities by OAI centers), medications other than statin (MIF form), and KL grade (based on baseline X-ray, grade 0/1/2/3/4). The units, levels, and categories of these variables are provided in Table 1 in the main text.

Assessment of missing data pattern using Little's test

To evaluate the pattern of missing data, we employed Little's test for missing completely at random, visual representation, and logistic regression models. The results indicated a non-random pattern of missing data (20) in the OAI dataset, with less than 2.8% missing values for all matching variables (Supplemental Table 2). Despite the non-random missing data pattern, we included all matching variables in multiple imputation models, as previous studies have suggested this approach to minimize potential associated biases (21).

Supplemental Tables

Supplemental Table 1. Osteoarthritis Initiative (OAI) datasets used in the analysis.

Dataset	Visit	Release version
All clinical	allclinical00	0.2.2
(data regarding all clinical information)	allclinical01	1.2.1
	allclinical03	3.2.1
	allclinical05	5.2.1
	allclinical06	6.2.1
Medical inventory form (MIF)	MIF00	0.2.2
(data regarding drug history)	MIF01	1.2.1
	MIF03	3.2.1
	MIF05	5.2.1
	MIF06	6.2.1
Enrollees	Enrollees	25
(data regarding baseline enrollment of OAI participants)		
Knee X-ray semi-quantitative reading (Kxr sq)	Kxr sq 00	0.8
MRI tracking and QA	mri00	0.2.2

(data regarding availability of MRI and	mri03	3.2.1
quality assessment)	mri06	6.2.1

Supplemental Table 2. Percentage of missing data of the covariate included in the multiple imputations and PS-matching methods.

Variables	Missing %
Subject characteristics	
Age	0.00%
No. of women	0.00%
Race, non-white	0.07%
Comorbidities and Risk factors	
PASE score	0.55%
BMI	0.10%
Waist circumference	0.21%
Abdominal (central) obesity	0.21%
Alcohol use	0.58%
Smoking	1.16%
Diabetes	2.12%
Hypertension	0.00%
CVA	1.61%
Heart attack	1.92%
Heart failure	1.30%

Peripheral artery disease	0.79%
Malignancy	1.61%
Advanced liver disease	1.64%
Kidney dysfunction	2.70%
COPD	2.05%
Peptic ulcer	2.81%
Charlson Comorbidity score	1.03%
KL grade	0.00%
Medication data	0.00%

BMI: Body Mass Index, COPD: Chronic Obstructive Pulmonary Disease, CVA: Cerebrovascular Accident, KL: Kellgren-Lawrence grade, PASE: Physical Activity for Elderly Scale, PS: Propensity-score.

Supplemental Table 3. Baseline characteristics of study groups as with and without/at-risk of KOA, included in the study before and after propensity-score matching according to statin use.

	With KOA (KL≥2)						Without/at-risk of KOA (KL<2)					
	Statin	Statin	SMD	Statin (-	Statin	SMD	Statin (-	Statin	SMD	Statin	Statin	SMD
	(-)	(+)		)	(+)		)	(+)		(-)	(+)	
	N: 1494	N: 1032		N: 847	N: 847		N: 2040	N: 1262		N: 1039	N: 1039	
Subject characteristics												
Age (year) [mean (SD)]	61.35 (9.21)	63.62 (8.32)	0.26	63.22 (9.13)	63.30 (8.16)	0.01	58.48 (8.86)	62.03 (8.84)	0.40	61.27 (9.25)	61.02 (8.76)	0.03
No. of women [N (%)]	914 (61.3)	552 (53.5)	0.16	432 (51.0)	461 (54.4)	0.07	1176 (57.6)	616 (48.8)	0.18	522 (50.2)	527 (50.7)	0.01

Race, non-white [N (%)]	348 (23.3)	248 (24.0)	0.02	185 (21.8)	198 (23.4)	0.04	317 (15.5)	196 (15.5)	0.00	142 (13.7)	157 (15.1)	0.04
Comorbidities and Risk factors												
PASE score [mean (SD)]	168.09 (82.08)	146.62 (73.85)	0.28	151.36 (76.42)	150.64 (75.90)	0.01	174.76 (83.15)	161.45 (81.26)	0.16	161.92 (80.00)	167.46 (82.90)	0.07
BMI (kg/m²) [mean (SD)]	28.82 (4.92)	30.39 (4.58)	0.33	29.92 (5.07)	29.90 (4.44)	0.00	27.08 (4.45)	28.27 (4.03)	0.28	27.90 (4.51)	27.89 (3.97)	0.00
Waist circumference, (cm) [mean (SD)]	102.55 (12.35)	106.55 (11.48)	0.34	105.40 (11.79)	105.46 (11.35)	0.01	98.16 (12.84)	102.03 (11.16)	0.32	101.10 (12.41)	100.88 (10.85)	0.02
Abdominal (central) obesity [N (%)]	1076 (72.1)	826 (80.0)	0.19	639 (75.4)	661 (78.0)	0.06	1224 (60.0)	870 (68.9)	0.19	693 (66.7)	688 (66.2)	0.01
Alcohol use [N (%)]			0.14			0.05			0.10			0.07

None	291 (19.5)	202 (19.6)	159 (18.8)	158 (18.7)	372 (18.2)	221 (17.5)	183 (17.6)	179 (17.2)
<1 drink/wk	558 (37.4)	428 (41.5)	335 (39.6)	348 (41.1)	737 (36.1)	472 (37.4)	365 (35.1)	383 (36.9)
1-3 drinks/wk	191 (12.8)	126 (12.2)	111 (13.1)	109 (12.9)	372 (18.2)	192 (15.2)	164 (15.8)	172 (16.6)
4-7 drinks/wk	247 (16.6)	128 (12.4)	105 (12.4)	106 (12.5)	301 (14.8)	193 (15.3)	172 (16.6)	152 (14.6)
8-14 drinks/wk	130 (8.7)	84 (8.1)	80 (9.4)	71 (8.4)	173 (8.5)	124 (9.8)	100 (9.6)	103 (9.9)
+15 drinks/wk	75 (5.0)	64 (6.2)	57 (6.7)	55 (6.5)	85 (4.2)	60 (4.8)	55 (5.3)	50 (4.8)
Smoking [N (%)]		0.13		0.06		0.16		0.05
Never smoked	840 (56.3)	522 (50.6)	458 (54.1)	437 (51.6)	1179 (57.8)	658 (52.1)	567 (54.6)	549 (52.8)

Past smoker		568 (38.1)	434 (42.1)		344 (40.6)	355 (41.9)		736 (36.1)	548 (43.4)		411 (39.6)	434 (41.8)	
Smoker < 14 cigarettes/day		62 (4.2)	50 (4.8)		31 (3.7)	37 (4.4)		77 (3.8)	30 (2.4)		35 (3.4)	30 (2.9)	
Smoker ≥ 14 cigarettes/day		22 (1.5)	26 (2.5)		14 (1.7)	18 (2.1)		48 (2.4)	26 (2.1)		26 (2.5)	26 (2.5)	
Diabetes [N (%)]		66 (4.4)	139 (13.5)	0.32	65 (7.7)	81 (9.6)	0.07	38 (1.9)	146 (11.6)	0.40	35 (3.4)	47 (4.5)	0.06
Hypertension [N (%)]		356 (23.9)	252 (24.4)	0.01	214 (25.3)	208 (24.6)	0.02	320 (15.7)	240 (19.0)	0.09	192 (18.5)	192 (18.5)	0.00
CVA [N (%)]		36 (2.4)	52 (5.0)	0.14	29 (3.4)	28 (3.3)	0.01	29 (1.4)	37 (2.9)	0.10	24 (2.3)	23 (2.2)	0.01
Heart attack [N (%)]		15 (1.0)	34 (3.3)	0.16	11 (1.3)	20 (2.4)	0.08	10 (0.5)	47 (3.7)	0.23	10 (1.0)	14 (1.3)	0.04

Heart failure [N (%)]	22 (1.5)	32 (3.1)	0.11	19 (2.2)	16 (1.9)	0.03	20 (1.0)	34 (2.7)	0.13	12 (1.2)	8 (0.8)	0.04
Peripheral artery disease [N (%)]	8 (0.5)	12 (1.2)	0.07	4 (0.5)	6 (0.7)	0.03	2 (0.1)	22 (1.7)	0.17	2 (0.2)	2 (0.2)	0.00
Malignancy [N (%)]	58 (3.9)	52 (5.0)	0.06	35 (4.1)	35 (4.1)	0.00	60 (2.9)	46 (3.6)	0.04	34 (3.3)	40 (3.8)	0.03
Advanced liver disease [N (%)]	0 (0.0)	0 (0.0)	0.00	0 (0.0)	0 (0.0)	0.00	10 (0.5)	2 (0.2)	0.06	4 (0.4)	0 (0.0)	0.09
Kidney dysfunction [N (%)]	14 (0.9)	10 (1.0)	0.00	10 (1.2)	9 (1.1)	0.01	11 (0.5)	30 (2.4)	0.15	9 (0.9)	11 (1.1)	0.02
COPD [N (%)]	26 (1.7)	27 (2.6)	0.06	17 (2.0)	13 (1.5)	0.04	41 (2.0)	36 (2.9)	0.06	30 (2.9)	27 (2.6)	0.02
Peptic ulcer [N (%)]	23 (1.5)	40 (3.9)	0.14	21 (2.5)	19 (2.2)	0.02	61 (3.0)	27 (2.1)	0.05	16 (1.5)	19 (1.8)	0.02

Charlson

Comorbidity score
[mean (SD)]

0.30	0.52	0.25	0.38	0.40	0.03	0.26	0.49	0.27	0.27	0.31	0.06
(0.73)	(0.99)		(0.83)	(0.86)		(0.73)	(0.92)		(0.67)	(0.69)	

KL grade [N (%)]

0.02	0.01	0.14	0.02
------	------	-------------	------

Grade 0	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1414 (69.3)	792 (62.8)	650 (62.6)	658 (63.3)
Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	626 (30.7)	470 (37.2)	389 (37.4)	381 (36.7)
Grade 2	958 (64.2)	666 (64.5)	540 (63.8)	539 (63.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade 3	436 (29.2)	302 (29.3)	255 (30.1)	254 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade 4	98 (6.6)	64 (6.2)	52 (6.1)	54 (6.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Medications

Diuretics [N (%)]	248 (16.6)	286 (27.7)	0.27	203 (24.0)	206 (24.3)	0.01	276 (13.5)	308 (24.4)	0.28	216 (20.8)	207 (19.9)	0.02
B blocker [N (%)]	172 (11.5)	228 (22.1)	0.29	148 (17.5)	158 (18.7)	0.03	192 (9.4)	266 (21.1)	0.33	154 (14.8)	168 (16.2)	0.04
Calcium channel blocker [N (%)]	118 (7.9)	166 (16.1)	0.25	100 (11.8)	108 (12.8)	0.03	98 (4.8)	148 (11.7)	0.25	90 (8.7)	92 (8.9)	0.01
Non-statin lipid-lowering drug [N (%)]	40 (2.7)	56 (5.4)	0.14	32 (3.8)	37 (4.4)	0.03	50 (2.5)	86 (6.8)	0.21	46 (4.4)	45 (4.3)	0.01
ACEI/ARB [N (%)]	272 (18.2)	310 (30.0)	0.28	218 (25.7)	209 (24.7)	0.02	268 (13.1)	390 (30.9)	0.44	228 (21.9)	239 (23.0)	0.03
Oral hypoglycemic [N (%)]	44 (2.9)	104 (10.1)	0.29	44 (5.2)	66 (7.8)	0.09	24 (1.2)	126 (10.0)	0.39	24 (2.3)	35 (3.4)	0.06
NSAID [N (%)]	256 (17.2)	230 (22.3)	0.13	173 (20.4)	162 (19.1)	0.03	246 (12.1)	184 (14.6)	0.07	143 (13.8)	152 (14.6)	0.03

Aspirin [N (%)]	36 (2.4)	40 (3.9)	0.08	28 (3.3)	29 (3.4)	0.01	36 (1.8)	70 (5.5)	0.20	34 (3.3)	35 (3.4)	0.01
SSRI [N (%)]	94 (6.3)	98 (9.5)	0.12	66 (7.8)	74 (8.7)	0.03	136 (6.7)	138 (10.9)	0.15	102 (9.8)	98 (9.4)	0.01
Tricyclic antidepressant [N (%)]	14 (0.9)	26 (2.5)	0.12	14 (1.7)	10 (1.2)	0.04	24 (1.2)	24 (1.9)	0.06	20 (1.9)	20 (1.9)	0.00
Sedative [N (%)]	64 (4.3)	60 (5.8)	0.07	43 (5.1)	41 (4.8)	0.01	84 (4.1)	92 (7.3)	0.14	68 (6.5)	66 (6.4)	0.01
Systemic corticosteroid [N (%)]	112 (7.5)	92 (8.9)	0.05	72 (8.5)	70 (8.3)	0.01	192 (9.4)	178 (14.1)	0.15	128 (12.3)	131 (12.6)	0.01
Thyroid hormones [N (%)]	160 (10.7)	116 (11.2)	0.02	76 (9.0)	95 (11.2)	0.08	192 (9.4)	144 (11.4)	0.07	101 (9.7)	113 (10.9)	0.04

Antineoplastic agents [N (%)]		38 (2.5)	32 (3.1)	0.03	26 (3.1)	22 (2.6)	0.03	34 (1.7)	36 (2.9)	0.08	25 (2.4)	29 (2.8)	0.02
Anticoagulants [N (%)]		34 (2.3)	30 (2.9)	0.04	19 (2.2)	22 (2.6)	0.02	30 (1.5)	36 (2.9)	0.10	22 (2.1)	23 (2.2)	0.01
Muscle quality measures													
Knee extension													
specific contractile force	(N/cm2)	6.85 (2.01)	6.77 (1.91)	0.04	6.81 (1.99)	6.82 (1.89)	0.00	7.27 (2.00)	7.00 (1.95)	0.14	7.25 (2.00)	7.09 (1.93)	0.08
[mean (SD)]													
Knee flexion													
maximum contractile force (N)		144.46 (67.10)	143.17 (66.58)	0.02	150.48 (71.07)	142.06 (65.37)	0.12	151.30 (70.63)	149.68 (72.40)	0.02	152.76 (71.55)	151.52 (73.86)	0.02
[mean (SD)]													

Knee flexion													
specific contractile force	(N/cm2)	4.39 (1.67)	4.24 (1.66)	0.09	4.35 (1.65)	4.22 (1.61)	0.08	4.78 (1.85)	4.58 (1.83)	0.11	4.70 (1.83)	4.66 (1.83)	0.03
[mean (SD)]													
Knee extension													
maximum contractile force (N)		338.63 (125.68)	347.50 (127.85)	0.07	350.20 (131.26)	348.50 (126.91)	0.01	364.02 (134.69)	357.44 (131.84)	0.05	366.77 (134.21)	360.75 (134.08)	0.05
[mean (SD)]													
Total thigh muscle CSA (mm2)	[mean (SD)]	9920.32 (2674.35)	10249.18 (2572.75)	0.13	10266.11 (2744.65)	10193.40 (2541.73)	0.03	9810.57 (2683.01)	10046.65 (2631.22)	0.09	9951.72 (2741.96)	9966.49 (2636.37)	0.01
Intra-MAT CSA (mm2)	[mean (SD)]	458.96 (359.60)	549.32 (345.83)	0.26	519.83 (385.70)	512.62 (321.50)	0.02	352.33 (234.31)	446.33 (310.24)	0.34	398.25 (264.63)	419.74 (292.99)	0.08

Total thigh muscles

contractile	%	95.25	94.53	0.22	94.80	94.85	0.01	96.33	95.49	0.31	95.91	95.70	0.08
		(3.37)	(3.29)		(3.41)	(3.13)		(2.34)	(2.98)		(2.59)	(2.90)	
[mean (SD)]													

ACEI: Angiotensin Converting Enzyme Inhibitor, ARB: Angiotensin Receptor Blocker, BMI: Body Mass Index, CSA: Cross-sectional Area, COPD: Chronic Obstructive Pulmonary Disease, CVA: Cerebrovascular Accident, Intra-MAT: Intra-muscular Adipose tissue, KL: Kellgren-Lawrence grade, KOA: Knee Osteoarthritis, NSAIDs: Non-steroidal Anti-inflammatory Drugs, PASE: Physical Activity for Elderly Scale, PS: Propensity-score, SMD: Standardized Mean Difference, SD: Standard Deviation, SSRI: Selective Serotonin Reuptake Inhibitor. A significant difference for SMD was defined as ≥ 0.1 and is shown as bold.

† Race of participants was categorized as white and non-white considering the small number of participants in each non-white race group.

* Abdominal obesity was defined as a waist circumference of ≥ 94 cm in men and ≥ 80 cm in women on physical examination according to international diabetes foundation criteria.

Supplemental Table 4. Baseline characteristics of the study participants included in sensitivity analysis of exclusion of participants with adherent and prevalent statin use (Sensitivity analysis #1) before and after propensity score matching according to statin use.

	All participants			PS-matched participants		
	Statin (-)	Statin (+)	SMD	Statin (-)	Statin (+)	SMD
	N: 3532	N: 836		N: 794	N: 794	
Subject characteristics						
Age (year) [mean (SD)]	59.69 (9.12)	61.32 (8.98)	0.179	61.10 (9.19)	61.21 (9.02)	0.012
No. of women [N (%)]	2090 (59.2)	436 (52.2)	0.142	419 (52.8)	422 (53.1)	0.008
Race, non-white [N (%)]†	665 (18.8)	186 (22.2)	0.085	153 (19.3)	167 (21.0)	0.044
Comorbidities and Risk factors						
PASE score [mean (SD)]	171.94 (82.75)	160.58 (81.78)	0.138	160.66 (79.16)	161.90 (82.39)	0.015
BMI (kg/m²) [mean (SD)]	27.81 (4.73)	29.03 (4.55)	0.262	29.12 (5.00)	28.92 (4.54)	0.043
Waist circumference, (cm) [mean (SD)]	100.01 (12.82)	103.01 (12.13)	0.240	103.58 (13.36)	102.74 (12.28)	0.065
Abdominal (central) obesity [N (%)]*	2300 (65.1)	594 (71.1)	0.128	573 (72.2)	558 (70.3)	0.042

Alcohol use per week [N (%)]			0.118			0.066
None	663 (18.8)	155 (18.5)		133 (16.8)	139 (17.5)	
<1 drink/wk	1295 (36.7)	335 (40.1)		334 (42.1)	324 (40.8)	
1-3 drinks/wk	563 (15.9)	110 (13.2)		105 (13.2)	106 (13.4)	
4-7 drinks/wk	548 (15.5)	112 (13.4)		95 (12.0)	105 (13.2)	
8-14 drinks/wk	303 (8.6)	78 (9.3)		87 (11.0)	76 (9.6)	
+15 drinks/wk	160 (4.5)	46 (5.5)		40 (5.0)	44 (5.5)	
Smoking [N (%)]			0.135			0.099
Never smoked	2019 (57.2)	431 (51.6)		395 (49.7)	418 (52.6)	
Past smoker	1304 (36.9)	335 (40.1)		343 (43.2)	308 (38.8)	
Smoker < 14 cigarettes/day	139 (3.9)	42 (5.0)		31 (3.9)	40 (5.0)	
Smoker ≥ 14 cigarettes/day	70 (2.0)	28 (3.3)		25 (3.1)	28 (3.5)	
Diabetes [N (%)]	104 (2.9)	66 (7.9)	0.220	36 (4.5)	53 (6.7)	0.093

Hypertension [N (%)]	676 (19.1)	204 (24.4)	0.128	198 (24.9)	192 (24.2)	0.018
CVA [N (%)]	65 (1.8)	28 (3.3)	0.095	16 (2.0)	24 (3.0)	0.064
Heart attack [N (%)]	25 (0.7)	14 (1.7)	0.089	7 (0.9)	7 (0.9)	0.001
Heart failure [N (%)]	42 (1.2)	18 (2.2)	0.075	14 (1.8)	12 (1.5)	0.020
Peripheral artery disease [N (%)]	10 (0.3)	6 (0.7)	0.062	2 (0.3)	4 (0.5)	0.041
Malignancy [N (%)]	118 (3.3)	28 (3.3)	0.001	28 (3.5)	26 (3.3)	0.014
Advanced liver disease [N (%)]	10 (0.3)	0 (0.0)	0.075	6 (0.8)	0 (0.0)	0.099
Kidney dysfunction [N (%)]	25 (0.7)	8 (1.0)	0.027	5 (0.6)	5 (0.6)	0.001
COPD [N (%)]	67 (1.9)	19 (2.3)	0.026	22 (2.8)	14 (1.8)	0.068
Peptic ulcer [N (%)]	84 (2.4)	24 (2.9)	0.031	26 (3.3)	20 (2.5)	0.045
Charlson Comorbidity index [mean (SD)]	0.28 (0.73)	0.39 (0.78)	0.151	0.33 (0.77)	0.34 (0.70)	0.014
KL grade [N (%)]			0.105			0.055
Grade 0	958 (27.1)	224 (26.8)		215 (27.1)	218 (27.5)	

Grade 1	436 (12.3)	124 (14.8)	109 (13.7)	112 (14.1)
Grade 2	98 (2.8)	32 (3.8)	38 (4.8)	32 (4.0)
Grade 3	1414 (40.0)	306 (36.6)	278 (35.0)	289 (36.4)
Grade 4	626 (17.7)	150 (17.9)	154 (19.4)	143 (18.0)

Medications

Diuretic [N (%)]	524 (14.8)	190 (22.7)	0.203	202 (25.4)	173 (21.8)	0.086
B blocker [N (%)]	364 (10.3)	126 (15.1)	0.144	109 (13.7)	111 (14.0)	0.007
Calcium channel blocker [N (%)]	216 (6.1)	100 (12.0)	0.205	81 (10.2)	77 (9.7)	0.017
Non-statin lipid-lowering drug [N (%)]	90 (2.5)	42 (5.0)	0.130	33 (4.2)	35 (4.4)	0.012
ACEI/ARB [N (%)]	540 (15.3)	192 (23.0)	0.196	183 (23.0)	173 (21.8)	0.030
Oral hypoglycemic [N (%)]	68 (1.9)	50 (6.0)	0.209	28 (3.5)	37 (4.7)	0.057
NSAIDs [N (%)]	502 (14.2)	168 (20.1)	0.157	162 (20.4)	152 (19.1)	0.032
Aspirin [N (%)]	72 (2.0)	34 (4.1)	0.118	29 (3.7)	22 (2.8)	0.050

SSRI [N (%)]	230 (6.5)	86 (10.3)	0.136	64 (8.1)	84 (10.6)	0.087
Tricyclic antidepressant [N (%)]	38 (1.1)	16 (1.9)	0.069	10 (1.3)	12 (1.5)	0.022
Sedative [N (%)]	148 (4.2)	34 (4.1)	0.006	30 (3.8)	34 (4.3)	0.026
Systemic corticosteroid [N (%)]	304 (8.6)	110 (13.2)	0.147	113 (14.2)	100 (12.6)	0.048
Thyroid hormones [N (%)]	352 (10.0)	92 (11.0)	0.034	87 (11.0)	88 (11.1)	0.004
Antineoplastic agents [N (%)]	72 (2.0)	22 (2.6)	0.039	20 (2.5)	20 (2.5)	0.001
Anticoagulants [N (%)]	64 (1.8)	12 (1.4)	0.030	6 (0.8)	8 (1.0)	0.027
Statins						
atorvastatin	0 (0.0)	270 (32.3)		0 (0.0)	252 (31.7)	
fluvastatin	0 (0.0)	4 (0.5)		0 (0.0)	2 (0.3)	
lovastatin	0 (0.0)	44 (5.3)		0 (0.0)	42 (5.3)	
pravastatin	0 (0.0)	58 (6.9)		0 (0.0)	58 (7.3)	
rosuvastatin	0 (0.0)	78 (9.3)		0 (0.0)	70 (8.8)	

simvastatin	0 (0.0)	382 (45.7)		0 (0.0)	370 (46.6)	
Muscle quality measures						
Knee extension maximum contractile force (N) [mean (SD)]	9856.93 (2679.52)	10186.68 (2716.31)	0.122	10086.83 (2731.41)	10145.45 (2707.85)	0.022
Knee extension specific contractile force (N/cm²) [mean (SD)]	397.37 (298.47)	473.94 (312.62)	0.251	475.02 (343.18)	465.55 (309.67)	0.029
Knee flexion maximum contractile force (N) [mean (SD)]	95.87 (2.87)	95.29 (2.82)	0.206	95.20 (3.28)	95.36 (2.74)	0.053
Knee flexion specific contractile force (N/cm²) [mean (SD)]	1062.19 (394.24)	1166.89 (403.65)	0.262	1158.77 (409.89)	1153.59 (395.07)	0.013
Total thigh muscle CSA (mm²) [mean (SD)]	353.32 (131.54)	352.28 (137.51)	0.008	353.58 (126.33)	351.81 (137.08)	0.013
Total thigh muscles intra-MAT CSA (mm²) [mean (SD)]	7.10 (2.01)	6.85 (2.06)	0.123	6.97 (1.97)	6.87 (2.07)	0.049

**Total thigh muscles contractile % [mean
(SD)]**

148.42 (69.24) 146.49 (72.23) 0.027 149.99 (64.67) 146.33 (72.02) 0.054

Data are presented in numbers of thighs. Statin users with >30 days of statin use before baseline visit (prevalent users) or adherent use of statins through all annual visits of 4-year follow-up were excluded. ACEI: Angiotensin-Converting Enzyme Inhibitor, ARB: Angiotensin Receptor Blocker, BMI: Body Mass Index, CSA: Cross-sectional Area, COPD: Chronic Obstructive Pulmonary Disease, CVA: Cerebrovascular Accident, Intra-MAT: Intra-muscular Adipose tissue, KL: Kellgren-Lawrence grade, N: Newton, NSAIDs: Non-steroidal Anti-inflammatory Drugs, PASE: Physical Activity for Elderly Scale, PS: Propensity-score, SMD: Standardized Mean Difference, SD: Standard Deviation, SSRI: Selective Serotonin Reuptake Inhibitor. A significant difference for SMD was defined as ≥ 0.1 and is shown as bold.

† Race of participants was categorized as white and non-white considering the small number of participants in each non-white race group.

* Abdominal obesity was defined as a waist circumference of ≥ 94 cm in men and ≥ 80 cm in women on physical examination according to international diabetes foundation criteria.

Supplemental Table 5. Sensitivity analysis results.

	Average Difference/year (95% CI), P
#1. Exclusion of adherent and prevalent statin users	
Muscle contractile force	
Knee extension maximum contractile force (N)	-2.15 (-4.35 - 0.05), P:0.056
Knee extension specific contractile force (N/cm2)	-0.05 (-0.10 - -0.01), P:0.018*
Knee flexion maximum contractile force (N)	0.01 (-1.22 - 1.23), P:0.993
Knee flexion specific contractile force (N/cm2)	-0.01 (-0.05 - 0.03), P:0.562
Muscle size & composition	
Total thigh muscle CSA (mm2)	7.14 (-10.03 - 24.32), P:0.415
Total thigh muscle Intra-MAT CSA (mm2)	7.45 (3.61 - 11.29), P:<0.001*
Total thigh muscles contractile %	-0.07 (-0.11 - -0.03), P:<0.001*
#2. Data imputation	
Muscle contractile force	
Knee extension maximum contractile force (N)	-2.21 (-3.67 - -0.75), P:0.003*
Knee extension specific contractile force (N/cm2)	-0.05 (-0.07 - -0.02), P:0.002*
Knee flexion maximum contractile force (N)	0.02 (-0.82 - 0.86), P:0.963
Knee flexion specific contractile force (N/cm2)	-0.00 (-0.03 - 0.02), P:0.733
Muscle size & composition	

Total thigh muscle CSA (mm2)	5.29 (-6.35 – 16.94), P:0.373
Total thigh muscle Intra-MAT CSA (mm2)	3.65 (1.04 – 6.26), P:0.006*
Total thigh muscles contractile %	-0.04 (-0.07 – -0.01), P:0.004*

#3. All patients cohort (without PS-matching)

Muscle contractile force

Knee extension maximum contractile force (N)	-1.70 (-2.89 – -0.52), P:0.005*
Knee extension specific contractile force (N/cm2)	-0.03 (-0.05 – -0.00), P:0.022*
Knee flexion maximum contractile force (N)	0.09 (-0.57 – 0.75), P:0.792
Knee flexion specific contractile force (N/cm2)	0.01 (-0.01 – 0.03), P:0.412

Muscle size & composition

Total thigh muscle CSA (mm2)	-6.02 (-15.82 – 3.79), P:0.229
Total thigh muscle Intra-MAT CSA (mm2)	5.60 (3.30 – 7.90), P:<0.001*
Total thigh muscles contractile %	-0.06 (-0.09 – -0.04), P:<0.001*

We conducted several sensitivity analyses to assess the impact of different factors on the results. Firstly, we evaluated the sensitivity of the results to the exclusion of adherent and prevalent statin users. This involved excluding statin users who had taken statins for more than 30 days before the baseline visit or who consistently adhered to statin use throughout the four-year follow-up period (Sensitivity analysis #1 in Figure 1). Secondly, we examined the sensitivity of the results to data imputation by excluding 437 participants with missing data in covariates (Sensitivity analysis #2 in Figure 1). Thirdly, we assessed the sensitivity of the results to the

propensity-score matching (PS-matching) methods by performing adjusted analyses on all included OAI participants (Sensitivity analysis #3 in Figure 1). In these analyses, linear mixed-effect regressions were utilized. For the sensitivity to the exclusion of adherent and prevalent statin users and data imputation, random slopes and intercepts were considered for clusters of matched participants, while a random intercept was included to account for both thighs in all three sensitivity analyses. To minimize the influence of knee osteoarthritis (KOA)-related knee joint pain on the assessment of muscle contractile force, all statistical models with muscle maximum and specific contractile forces as dependent variables were adjusted for baseline knee joint pain, measured by the Western Ontario and McMaster Universities (WOMAC) pain score. In addition, we used CSA (Cross-sectional Area) and Intra-MAT (Intra-muscular Adipose Tissue) as relevant variables in the analysis.

* Significant FDR corrected p-value

Supplemental Figures

Supplemental Figure 1. Illustration of the study muscle biomarkers.




Illustration of study outcome variables. CSA: Cross-sectional Area, IMT: Inter-muscular Tissue, Inter-MAT: Inter-muscular Adipose Tissue, Intra-MAT: Intra-muscular Adipose Tissue, SCF: Subcutaneous Fat.

Appendix References

1. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, Gee JC. N4ITK: Improved N3 Bias Correction. *IEEE Transactions on Medical Imaging* 2010;29(6):1310-1320.
2. Kemnitz J, Wirth W, Eckstein F, Culvenor AG. The role of thigh muscle and adipose tissue in knee osteoarthritis progression in women: data from the Osteoarthritis Initiative. *Osteoarthritis and cartilage* 2018;26(9):1190-1195.
3. Cotofana S, Hudelmaier M, Wirth W, Himmer M, Ring-Dimitriou S, Sanger AM, Eckstein F. Correlation between single-slice muscle anatomical cross-sectional area and muscle volume in thigh extensors, flexors and adductors of perimenopausal women. *Eur J Appl Physiol* 2010;110(1):91-97.
4. Kemnitz J, Baumgartner CF, Eckstein F, Chaudhari A, Ruhdorfer A, Wirth W, Eder SK, Konukoglu E. Clinical evaluation of fully automated thigh muscle and adipose tissue segmentation using a U-Net deep learning architecture in context of osteoarthritic knee pain. *Magma* 2020;33(4):483-493.
5. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation. In: Navab N, Hornegger J, Wells WM, Frangi AF, eds. *Medical Image Computing and Computer-Assisted Intervention – MICCAI 2015*. Cham: Springer International Publishing, 2015; p. 234-241.
6. Avants BB, Tustison N, Song G. Advanced normalization tools (ANTs). *Insight j* 2009;2(365):1-35.

7. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. *Journal of Clinical Lipidology*. 2014;8(3, Supplement):S58-S71.
8. Thompson PD, Parker BA, Clarkson PM, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. *Preventive cardiology*. 2010;13(3):104-111.
9. Loenneke JP, Loprinzi PD. Statin use may reduce lower extremity peak force via reduced engagement in muscle-strengthening activities. *Clin Physiol Funct Imaging*. 2018;38(1):151-154.
10. Willcocks RJ, Forbes SC, Walter GA, et al. Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy. *JAMA Network Open*. 2021;4(1):e2031851-e2031851.
11. Verdú-Díaz J, Alonso-Pérez J, Nuñez-Peralta C, et al. Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. *Neurology*. 2020;94(10):e1094-e1102.
12. Dahlqvist JR, Widholm P, Leinhard OD, Vissing J. MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy. *Annals of Neurology*. 2020;88(4):669-681.
13. Murai J, Nishizawa H, Otsuka A, et al. Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. *Cardiovascular Diabetology*. 2018;17(1):112.
14. Sizoo D, de Heide LJM, Emous M, van Zutphen T, Navis G, van Beek AP. Measuring Muscle Mass and Strength in Obesity: a Review of Various Methods. *Obesity Surgery*. 2021;31(1):384-393.

15. D'Souza A, Bolsterlee B, Herbert RD. Intramuscular Fat in the Medial Gastrocnemius Muscle of People Who Have Had a Stroke. *Frontiers in Bioengineering and Biotechnology*. 2020;8(613).
16. Morse CI, Thom JM, Reeves ND, Birch KM, Narici MV. In vivo physiological cross-sectional area and specific force are reduced in the gastrocnemius of elderly men. 2005;99(3):1050-1055.
17. Culvenor AG, Felson DT, Niu J, et al. Thigh Muscle Specific-Strength and the Risk of Incident Knee Osteoarthritis: The Influence of Sex and Greater Body Mass Index. *Arthritis Care & Research*. 2017;69(8):1266-1270.
18. Culvenor AG, Hamler FC, Kemnitz J, Wirth W, Eckstein F. Brief Report: Loss of Muscle Strength Prior to Knee Replacement: A Question of Anatomic Cross-Sectional Area or Specific Strength? *Arthritis Rheumatol*. 2018;70(2):222-229.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A consensus statement from the International Diabetes Federation. *Diabet Med* 2006;23(5):469-480.
20. Li C. Little's test of missing completely at random. *Stata Journal* 2013;13(4):795-809.
21. Resseguier N, Giorgi R, Paoletti X. Sensitivity analysis when data are missing not-at-random. *Epidemiology* 2011;22(2):282.